Access a PDF of the poster by clicking on the hyperlinked title below.

  • ABSTRACT 5547
    TITLE: Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): activity and safety analyses in Phase I pooled expansion cohorts.
  • ABSTRACT 5553
    TITLE: Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.
  • ABSTRACT TPS5607
    FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.

For more information, please contact scientificaffairs@immunogen.com.

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue